ORMP

Oramed Pharmaceuticals Inc. - 10-Q Summary (Period Ended May 31, 2011)

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Oramed Pharmaceuticals Inc., a development-stage biotechnology company focused on orally ingestible insulin and other polypeptide delivery systems. The reporting period covers the nine months ended May 31, 2011. The company is reincorporated in Delaware and operates primarily through its Israeli subsidiary, Oramed Ltd. The company has not yet realized any revenues from planned operations and relies on financing and government grants to fund research and development (R&D).

Key Financial Metrics

Note: The Net Income for the three-month period is driven by a non-recurring gain on the sale of an investment.

Material Changes vs. Prior Period

• Net Income vs. Loss: The company reported a net income of $457,370 for the three months ended May 31, 2011, compared to a net loss of $806,219 in the same period in 2010. This reversal is primarily due to a Gain on Sale of Investment of $1,033,004 resulting from the sale of a 47% stake in a joint venture (Entera Bio Ltd.) to D.N.A Biomedical Solutions Ltd.
• Operating Expenses: R&D expenses decreased slightly to $869,166 (nine months 2011) from $871,285 (nine months 2010). G&A expenses increased to $971,143 from $944,074, largely due to higher professional fees offset by lower stock-based compensation.
• Liquidity: Cash and cash equivalents increased from $1,199,638 (August 31, 2010) to $1,920,132 (May 31, 2011), supported by short-term bank deposits of $1,795,765. This increase was funded by private equity placements totaling approximately $3.7 million during the period.
• Equity: Shares outstanding increased from 57.6 million to 70.1 million due to private placements and stock issued for services.

Outlook, Risks, and Management Commentary

• Going Concern Risk: Management explicitly states there is substantial doubt about the company's ability to continue as a going concern. The company has an accumulated deficit of $13.8 million and negative cash flow from operations. It estimates a need for approximately $5.3 million to fund operations for the next 12 months.
• Financing Strategy: The company is actively pursuing additional financing through public or private equity markets and expects to receive further funding from the Office of the Chief Scientist of Israel (OCS). Recent private placements raised $3.36 million (Nov-Mar 2011) and $359,800 (April 2011).
• Product Development: The company continues R&D on its oral insulin capsule (ORMD0801) and an oral GLP-1 analog. It plans to file an Investigational New Drug (IND) application with the FDA. Recent clinical trials in Type 1 and Type 2 diabetes patients have shown positive results.
• Joint Venture Exit: The sale of the Entera Bio stake eliminated the requirement for further capital contributions to that entity and generated a significant non-cash gain, though the company retains a 3% royalty interest on Entera's net revenues.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of May 31, 2011.

Key Facts for Investor Verification

• Cash Runway: Verify if the company has secured the estimated $5.3 million required for the next 12 months, as current cash reserves ($1.9M) and short-term deposits ($1.8M) may be insufficient without new capital.
• Non-Recurring Gain: Understand that the recent net income is driven by a one-time gain on the sale of an investment, not operational profitability. Core operations remain loss-making.
• Regulatory Path: Monitor progress on the FDA IND application for the oral insulin capsule, which is critical for future commercialization.
• Government Grants: Confirm the status and terms of funding from the Israeli Office of the Chief Scientist, which offsets a portion of R&D expenses but carries royalty obligations on future product sales.
• Internal Controls: Assess the implications of the ineffective disclosure controls and procedures on the reliability of future financial reporting.